BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25986720)

  • 1. Clinical development of siltuximab.
    Davis CC; Shah KS; Lechowicz MJ
    Curr Oncol Rep; 2015 Jul; 17(7):29. PubMed ID: 25986720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
    Kurzrock R; Voorhees PM; Casper C; Furman RR; Fayad L; Lonial S; Borghaei H; Jagannath S; Sokol L; Usmani SZ; van de Velde H; Qin X; Puchalski TA; Hall B; Reddy M; Qi M; van Rhee F
    Clin Cancer Res; 2013 Jul; 19(13):3659-70. PubMed ID: 23659971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
    van Rhee F; Casper C; Voorhees PM; Fayad LE; van de Velde H; Vermeulen J; Qin X; Qi M; Tromp B; Kurzrock R
    Oncotarget; 2015 Oct; 6(30):30408-19. PubMed ID: 26327301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Siltuximab: first global approval.
    Markham A; Patel T
    Drugs; 2014 Jul; 74(10):1147-52. PubMed ID: 24958337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
    van Rhee F; Wong RS; Munshi N; Rossi JF; Ke XY; Fosså A; Simpson D; Capra M; Liu T; Hsieh RK; Goh YT; Zhu J; Cho SG; Ren H; Cavet J; Bandekar R; Rothman M; Puchalski TA; Reddy M; van de Velde H; Vermeulen J; Casper C
    Lancet Oncol; 2014 Aug; 15(9):966-74. PubMed ID: 25042199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of siltuximab: impact of disease state.
    Nikanjam M; Yang J; Capparelli EV
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):993-1001. PubMed ID: 31482226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Siltuximab: a new option for the management of Castleman's disease.
    Barquero N
    Drugs Today (Barc); 2015 Jan; 51(1):21-8. PubMed ID: 25685858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.
    van Rhee F; Rothman M; Ho KF; Fleming S; Wong RS; Fosså A; Dispenzieri A; Cavet J; Munshi N; Vermeulen J; Casper C
    Patient; 2015 Apr; 8(2):207-16. PubMed ID: 25736164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Siltuximab for multicentric Castleman disease.
    Liu YC; Stone K; van Rhee F
    Expert Rev Hematol; 2014 Oct; 7(5):545-57. PubMed ID: 25110138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
    Sun Y; Wang D; Salvadore G; Hsu B; Curran M; Casper C; Vermeulen J; Kent JM; Singh J; Drevets WC; Wittenberg GM; Chen G
    Brain Behav Immun; 2017 Nov; 66():156-164. PubMed ID: 28676350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.
    Ferrario A; Merli M; Basilico C; Maffioli M; Passamonti F
    Expert Opin Investig Drugs; 2017 Mar; 26(3):367-373. PubMed ID: 28140696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.
    Morra DE; Pierson SK; Shilling D; Nemat S; Appiani C; Guilfoyle M; Tendler C; van Rhee F; Fajgenbaum DC
    Br J Haematol; 2019 Jan; 184(2):232-241. PubMed ID: 30203839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease.
    Deisseroth A; Ko CW; Nie L; Zirkelbach JF; Zhao L; Bullock J; Mehrotra N; Del Valle P; Saber H; Sheth C; Gehrke B; Justice R; Farrell A; Pazdur R
    Clin Cancer Res; 2015 Mar; 21(5):950-4. PubMed ID: 25601959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.
    Lyseng-Williamson KA
    BioDrugs; 2015 Dec; 29(6):399-406. PubMed ID: 26394632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of Castleman's disease with siltuximab - case report and review of literature.
    Adam Z; Zeman D; Chodacki A; Pour L; Horváth T; Benda P; Adamová Z; Krejčí M; Tomíška M; Boichuk I; Král Z
    Klin Onkol; 2023; 37(4):320-329. PubMed ID: 38195387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.
    Tonialini L; Bonfichi M; Ferrero S; Malipiero G; Nozza A; Argnani L; Zinzani PL
    Hematol Oncol; 2018 Oct; 36(4):689-692. PubMed ID: 30074630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease.
    Min GJ; Jeon YW; Park SS; Park S; Shin SH; Yahng SA; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Kim DW; Lee JW; Cho SG
    Korean J Intern Med; 2021 Mar; 36(2):424-432. PubMed ID: 32088937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose selection of siltuximab for multicentric Castleman's disease.
    Mayer CL; Xie L; Bandekar R; Qi M; van de Velde H; Reddy M; Qin X; Davis HM; Puchalski TA
    Cancer Chemother Pharmacol; 2015 May; 75(5):1037-45. PubMed ID: 25784388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of siltuximab in the treatment of multicentric Castleman's disease.
    Sarosiek S; Shah R; Munshi NC
    Ther Adv Hematol; 2016 Dec; 7(6):360-366. PubMed ID: 27904739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of siltuximab on patient-related outcomes in multicentric Castleman's disease.
    Sitenga J; Aird G; Ahmed A; Silberstein PT
    Patient Relat Outcome Meas; 2018; 9():35-41. PubMed ID: 29391839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.